Spotlight On... Inovio pays $5.5M for jet delivery tech

Inovio Pharmaceuticals ($INO) shelled out $5.5 million for Bioject Medical Technologies' assets, getting its hands on needle-free jet injection technology with plans to incorporate the tech with its own. Inovio hopes to use Bioject's devices, which use high pressure gas or springs to propel liquid medicine into skin for immunization, with its DNA vaccines. Though it doesn't market any vaccines, Inovio's clinical pipeline includes vaccines for flu, HIV, Ebola, and MERS and preclinical programs in Zika, dengue, Chikungunya and RSV. It also has proof-of-principle human data showing a "significant" immune response for its universal flu vaccine and HIV DNA vaccine. Release

> A late flu outbreak is active in 37 U.S. states, according to a recent CDC report. Report

> New research shows that vaccine refusal is contributing to outbreaks of measles and pertussis in the U.S. More


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> German biotech Medigene said a data and safety monitoring board recommended advancing the company's dendritic cell vaccine to Phase II in acute myeloid leukemia. Release

> Brazil's Butantan Institute signed on with stabilization technology specialist ViveBio for work on a Phase III dengue vaccine trial. Release

Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.